Ann: December 2024 Quarterly Update and Appendix 4C, page-4

I found that to be too funny.... has anyone known such a question to be posed in ASX reporting?

It has been clearly and often disclosed that the Phase 1b trial is ongoing to derive more data on PTCL patients because more evaluable data is required to progress PTX-100 to Phase 2 in this specific TCL indication.

Perhaps, SYC got sick and tired of the lack of patience (pardon the pun) from unrealistic SHs. Maybe it is time for the new CEO to address the matter and provide (further) clarification.